Telomir Pharmaceuticals, Inc. reported a net loss of $10.4 million for the fiscal year ending December 31, 2025, a decrease from a loss of $16.5 million in the previous year. The company, which is in the preclinical stage of developing its lead investigational compound, Telomir-1, has not generated any revenue to date. Total operating costs for 2025 were approximately $10.5 million, down from $12.2 million in 2024. The reduction in costs was primarily attributed to a decrease in general and administrative expenses, which fell to $8.1 million from $9.6 million, while research and development expenses increased slightly to $2.4 million from $2.2 million.
In terms of strategic developments, Telomir Pharmaceuticals is in the process of merging with TELI Pharmaceuticals, a private company. The merger agreement, which was amended in February 2026, aims to consolidate the rights to Telomir-1 under a single public company structure, thereby simplifying global development and partnership efforts. The merger is contingent upon TELI maintaining at least $1 million in cash or marketable securities and is expected to enhance the company’s operational capabilities and market presence.
Operationally, Telomir Pharmaceuticals has focused on advancing its research and development activities, particularly for Telomir-1, which is designed to modulate intracellular metal balance and address age-related diseases. The company plans to submit an Investigational New Drug (IND) application in 2026, with the goal of initiating a Phase 1/2 clinical trial thereafter. As of the end of 2025, the company had approximately $7.3 million in cash and cash equivalents, which it expects will fund operations through the first quarter of 2027.
The company has also reported significant liquidity needs, with a reliance on equity financing to support its operations. In 2025, Telomir raised $9.7 million through various financing activities, including an initial public offering and stock purchase agreements with related parties. However, the company acknowledges that it will need to secure additional funding to continue its development programs and achieve its business objectives, particularly as it advances toward clinical trials.
Looking ahead, Telomir Pharmaceuticals is optimistic about the potential of Telomir-1 in treating various age-related conditions and oncology indications. The company is actively evaluating opportunities to expand its pipeline and is committed to addressing the underlying biological drivers of aging. However, it recognizes the inherent risks and uncertainties associated with drug development, including the potential for clinical trials to yield unfavorable results or for regulatory approvals to be delayed or denied.
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals develops innovative small molecule therapies targeting cellular metal imbalances, oxidative stress, and telomere maintenance. Its lead candidate, Telomir-1, aims to treat age-related diseases, rare genetic disorders like Wilson’s disease and Progeria, metabolic conditions such as Type 2 diabetes, and viral infections. The company focuses on preclinical research, regulatory approval, and potential market expansion in aging, neurodegeneration, and chronic diseases.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.